160 related articles for article (PubMed ID: 14641611)
1. Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (Omalizumab).
Kopp MV; Mayatepek E; Engels E; Brauburger J; Riedinger F; Ihorst G; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2003 Oct; 14(5):401-4. PubMed ID: 14641611
[TBL] [Abstract][Full Text] [Related]
2. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
Kopp MV; Stenglein S; Kamin W; Friedrichs F; von Berg A; Zielen S; Hamelmann E; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2007 Sep; 18(6):523-7. PubMed ID: 17680911
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis.
Kuehr J; Brauburger J; Zielen S; Schauer U; Kamin W; Von Berg A; Leupold W; Bergmann KC; Rolinck-Werninghaus C; Gräve M; Hultsch T; Wahn U
J Allergy Clin Immunol; 2002 Feb; 109(2):274-80. PubMed ID: 11842297
[TBL] [Abstract][Full Text] [Related]
5. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
Stock P; Rolinck-Werninghaus C; Wahn U; Hamelmann E
BioDrugs; 2007; 21(6):403-10. PubMed ID: 18020623
[TBL] [Abstract][Full Text] [Related]
6. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
7. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.
Klunker S; Saggar LR; Seyfert-Margolis V; Asare AL; Casale TB; Durham SR; Francis JN;
J Allergy Clin Immunol; 2007 Sep; 120(3):688-95. PubMed ID: 17631952
[TBL] [Abstract][Full Text] [Related]
9. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
[TBL] [Abstract][Full Text] [Related]
10. Role of immunmodulators in allergen-specific immunotherapy.
Kopp MV
Allergy; 2011 Jun; 66(6):792-7. PubMed ID: 21332502
[TBL] [Abstract][Full Text] [Related]
11. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
12. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy and influence on urinary leukotrienes in seasonal pediatric allergy.
Yuksel H; Tanac R; Gousseinov A; Demir E
J Investig Allergol Clin Immunol; 1999; 9(5):305-13. PubMed ID: 10582199
[TBL] [Abstract][Full Text] [Related]
14. Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?
Verbruggen K; Van Cauwenberge P; Bachert C
Int Arch Allergy Immunol; 2009; 148(2):87-98. PubMed ID: 18799888
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis.
Nayak A; Casale T; Miller SD; Condemi J; McAlary M; Fowler-Taylor A; Della Cioppa G; Gupta N
Allergy Asthma Proc; 2003; 24(5):323-9. PubMed ID: 14619332
[TBL] [Abstract][Full Text] [Related]
16. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
Bush RK
Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
Casale TB; Busse WW; Kline JN; Ballas ZK; Moss MH; Townley RG; Mokhtarani M; Seyfert-Margolis V; Asare A; Bateman K; Deniz Y;
J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
[TBL] [Abstract][Full Text] [Related]
18. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial.
Chaker AM; Shamji MH; Dumitru FA; Calderon MA; Scadding GW; Makatsori M; Jones I; He QA; Subramanian KK; Arm JP; Durham SR; Schmidt-Weber CB
J Allergy Clin Immunol; 2016 Feb; 137(2):452-461.e9. PubMed ID: 26531865
[TBL] [Abstract][Full Text] [Related]
19. Experience with monoclonal antibodies in allergic mediated disease: seasonal allergic rhinitis.
Casale TB
J Allergy Clin Immunol; 2001 Aug; 108(2 Suppl):S84-8. PubMed ID: 11498678
[TBL] [Abstract][Full Text] [Related]
20. Treatment with a combination of anti-IgE and specific immunotherapy for allergic rhinitis and asthma.
Hamelmann E; Rolinck-Werninghaus C; Wahn U; Kopp MV
Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2009; 96():303-13; discussion 313-5. PubMed ID: 20799475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
